Megan Williams
Acute Care · Tupelo, MSNPI 1922599752
Payments from drug & device makers
Across 548 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Inspire Medical Systems, Inc.$2K
- Boehringer Ingelheim$1K
- Harmony Biosciences LLC$529
- Regeneron Healthcare Solutions, Inc.$367
- plus $4K from 30 others
What the payments were for
- Travel & lodging$5986%
- Food & beverage$10,18494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 159 | $1,919 |
| AstraZeneca | 62 | $1,630 |
| Inspire Medical Systems, Inc. | 18 | $1,514 |
| Boehringer Ingelheim | 59 | $1,014 |
| Harmony Biosciences LLC | 22 | $529 |
| Regeneron Healthcare Solutions, Inc. | 17 | $367 |
| Jazz Pharmaceuticals Inc. | 17 | $363 |
| Sanofi | 18 | $357 |
| Mallinckrodt Hospital Products Inc. | 22 | $348 |
| Novartis | 20 | $330 |
| Merck | 16 | $303 |
| United Therapeutics Corporation | 15 | $277 |
| Electromed, Inc. | 16 | $228 |
| Bayer | 12 | $204 |
| ANI Pharmaceuticals, Inc. | 6 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $171 |
| Verona Pharma, Inc. | 9 | $139 |
| Genentech USA, Inc. | 8 | $133 |
| Mylan Specialty L.p. | 8 | $125 |
| Grifols USA, LLC | 4 | $82 |
| La Jolla Pharmaceutical Company | 5 | $75 |
| Amgen | 4 | $67 |
| Stryker | 1 | $53 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Viatris Specialty LLC | 2 | $51 |
| Pulmonx Corporation | 2 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Philips North America LLC | 2 | $35 |
| Baxter Healthcare | 2 | $30 |
| Fisher & Paykel Healthcare Inc | 1 | $21 |
| Ambu Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $17 |
| Resmed Corp | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Liquidia Technologies, Inc. | 1 | $15 |
| Breas Medical, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,782 in reported general payments places this provider in the 95th percentile of 223 acute care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 29 | $384,172 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 265 | $188,088 |
| Dupixent PenDupilumab | 16 | $60,384 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $55,255 |
| XolairOmalizumab | 21 | $43,652 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $40,239 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $25,826 |
| SunosiSolriamfetol Hcl | 13 | $11,155 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $9,791 |
| Spiriva RespimatTiotropium Bromide | 13 | $7,841 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 248 | $7,533 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,779 |
| Ventolin HfaAlbuterol Sulfate | 56 | $3,816 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,803 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,014 | $401,80458 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,919 | $259,932417 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,630 | $59,05795 claims |
| Axsome Therapeutics, Inc.Sunosi | $51 | $11,15513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 acute care providers in Mississippi.
Other acute care in Tupelo
- Christopher BellTupelo$348K
- Starla HortonTupelo$3K
- Robin JacksonTupelo$3K
- Cynthia SmithTupelo$3K
- Kathleen ArnoldOcean Springs$217K
- Gavin GistOxford$42K
- Jamie DamicoOcean Springs$17K
- Dylan BoydHattiesburg$15K
- Melinda ClarkStarkville$14K
- Michelle TaylorGulfport$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.